Abacavir Sulfate Lamivudine

證據等級: L5

預測適應症: 0 個

Abacavir Sulfate + Lamivudine: Antiretroviral Combination — No Repurposing Predictions Available

One-Sentence Summary

Abacavir Sulfate + Lamivudine is a well-established dual nucleoside reverse transcriptase inhibitor (NRTI) combination used globally for HIV-1 infection treatment (marketed as Epzicom/Kivexa in the US/EU). However, this drug combination is not registered in the Taiwan TFDA database, and the TxGNN pipeline returned no predicted repurposing indications for this candidate. As a result, this report documents the data gaps and provides a decision recommendation based on available evidence.

Quick Overview

Item	Content
Original Indication	HIV-1 infection (antiretroviral treatment) — sourced from general medical knowledge; not in Taiwan TFDA
Predicted New Indication	No prediction available
TxGNN Prediction Score	N/A
Evidence Level	L5 (model prediction only — but no prediction generated)
Taiwan Market Status	✗ Not marketed
Number of Approved Licenses (Taiwan)	0
Recommended Decision	Hold

Why No Prediction Was Generated

The TxGNN pipeline requires a valid DrugBank ID and a mapped drug node in the knowledge graph to generate repurposing predictions. For this candidate, the following issues were identified:

DrugBank ID is null: The combination “ABACAVIR SULFATE; LAMIVUDINE” was not successfully mapped to a DrugBank entry, preventing knowledge graph traversal. Each component (Abacavir: DB01048; Lamivudine: DB00709) has individual DrugBank records, but the combination query failed.
No Taiwan TFDA registration: TFDA query returned 0 results (query ID 1), meaning this combination is not approved or registered in Taiwan’s drug database.
DDI data not found: No drug-drug interaction data was retrievable under this combined query string.

Currently, detailed mechanism of action data is not available from the Evidence Pack. Based on known pharmacological information, Abacavir + Lamivudine belongs to the NRTI class, inhibiting HIV reverse transcriptase to suppress viral replication. Its efficacy in HIV-1 infection is well-established globally, though mechanistic applicability to other conditions (e.g., hepatitis B, for Lamivudine alone) would require separate TxGNN evaluation per individual component.

Clinical Trial Evidence

Currently no related clinical trials registered under this combined drug query via the TxGNN pipeline.

Note: Extensive clinical trial data exists for the individual components (Abacavir, Lamivudine) and the combination in HIV treatment, but these are not surfaced here due to the absence of TxGNN predictions.

Literature Evidence

Currently no related literature available via the TxGNN pipeline for this candidate.

Taiwan Market Information

This combination is not registered in the Taiwan TFDA database. No license records exist.

Item	Detail
TFDA Query Date	2026-03-24
Query Result	0 records found
Market Status	Not marketed in Taiwan

For reference: Abacavir + Lamivudine is marketed internationally as Epzicom (US, GlaxoSmithKline) and Kivexa (EU), approved for HIV-1 infection in adults and pediatric patients. These approvals are outside the scope of this Taiwan-focused Evidence Pack.

Safety Considerations

All safety data for this candidate returned as unavailable in the current Evidence Pack. Please refer to the package insert (Epzicom/Kivexa SmPC) for safety information.

Key known clinical warnings (from published prescribing information, not from this Evidence Pack):

Black Box Warning: Hypersensitivity reactions to Abacavir (HLA-B*5701 screening required before initiation); Lactic acidosis and severe hepatomegaly with steatosis.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN pipeline was unable to generate any repurposing predictions for this drug combination due to a failed DrugBank ID mapping and the absence of Taiwan TFDA registration data. Without a valid prediction, there is no repurposing hypothesis to evaluate.

To proceed, the following is needed:

Re-query by individual component: Run TxGNN separately for Abacavir (DB01048) and Lamivudine (DB00709) to retrieve individual repurposing predictions, then assess combination feasibility.
Resolve DrugBank mapping: The combined query string “ABACAVIR SULFATE; LAMIVUDINE” failed mapping. Submit individual INN names to DrugBank API to retrieve DrugBank IDs.
Confirm Taiwan regulatory status: Verify whether any generics or branded combinations are pending TFDA registration.
Populate MOA data: Query DrugBank API for mechanism of action entries for each component to enable mechanistic plausibility analysis.
Re-run TxGNN pipeline: After resolving the above gaps, re-run the full prediction pipeline and generate a new Evidence Pack with valid predicted_indications.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.